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Abstract
Background: Colorectal cancer (CRC) is closely linked to Wnt signalling, with 94 % of cases exhibiting a Wnt related
mutation. ROR2 is a receptor tyrosine kinase that is thought to repress β-catenin dependent Wnt signalling. Our
study aims to determine if ROR2 is epigenetically silenced in CRC and determine if in vitro silencing of ROR2
potentiates Wnt signalling, and alters the proliferative, migratory or invasive potential of cells.
Methods: ROR2 expression was examined in CRC cell lines and patient adenomas using qRT-PCR, while COBRA and
bisulphite sequencing was used to analyse ROR2 promoter methylation. 258 patient primary tumour samples from
publicly available databases were also examined for ROR2 expression and methylation. In addition, the functional
effects of ROR2 modulation were investigated in HCT116 cells following ROR2 siRNA knockdown and in RKO and
SW620 cells following ectopic ROR2 expression.
Results: Reduced ROR2 expression was found to correlate with ROR2 promoter hypermethylation in colorectal
cancer cell lines, carcinomas and adenomas. ROR2 expression was downregulated in 76.7 % (23/30) of CRC cell lines
with increasing ROR2 promoter hypermethylation correlating with progressively lower expression. Analysis of 239
primary tumour samples from a publicly available cohort also found a significant correlation between reduced ROR2
expression and increased promoter methylation. Methylation analysis of 88 adenomas and 47 normal mucosa
samples found greater percentage of adenoma samples to be methylated. Additional analysis also revealed that
adenoma samples with reduced ROR2 expression also possessed ROR2 promoter hypermethylation. ROR2
knockdown in the CRC cell line HCT116 significantly decreased expression of the β-catenin independent Wnt
targets genes JNK and NFATC1, increased cellular proliferation and migration but decreased invasion. When ROR2
was ectopically expressed in RKO and SW620 cells, there was no significant change to either cellular proliferation or
migration.
Conclusion: ROR2 is frequently epigenetically inactivated by promoter hypermethylation in the early stages of colorectal
neoplasia and this may contribute to colorectal cancer progression by increasing cellular proliferation and migration.
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Background
Colorectal cancer (CRC) is the third most common cancer
worldwide with an estimated 1 million cases each year
contributing to over 608,000 deaths [1–3]. CRCs develop
from benign intraepithelial neoplasms known as aden-
omas, which progress to cancer after an accumulation of
mutations [4, 5]. The Wnt signalling pathway is frequently
altered in CRC with ~94 % of cases possessing a mutation
in a Wnt pathway gene [6]. One of the early precipitating
events for colorectal adenoma development is mutation of
the APC gene, an important tumour suppressor and regu-
lator of β-catenin dependent Wnt signals [5, 7, 8]. APC
along with AXIN and GSK3β are responsible for degrad-
ation of cytosolic β-catenin and loss of APC leads to β-
catenin accumulation, Wnt pathway hyperactivation and
increased cellular proliferation and migration [8–15].
In contrast, the β-catenin independent Wnt pathway af-
fects planar cell polarity (PCP), cell adhesion and motility
and is not reliant on β-catenin levels [16–20]. The receptor
tyrosine kinase-like orphan receptor 2 (ROR2) is a receptor
tyrosine kinase which binds with WNT5A to activate the
β-catenin independent Wnt pathway [21–23]. In addition
to activating β-catenin independent Wnt/JNK signalling,
ROR2 and WNT5A interaction has been shown to antag-
onise downstream targets of β-catenin dependent Wnt;
specifically inhibition of AXIN2 expression and the TCF/
LEF transcription factors [16, 20, 23–26]. Consistent with
its reported antagonism of β-catenin dependent Wnt sig-
nals, a 2010 study found ROR2 to be silenced in colorectal
cancer, resulting in increased cellular proliferation [27].
However, other reports in colorectal cancer, melanoma and
osteosarcoma have found elevated ROR2 expression in tu-
mours compared to normal tissue [28–32]. These conflict-
ing reports have raised questions as to the role ROR2 plays
in cancer and presents the possibility that the downstream
effects of ROR2 are dependent on other Wnt genes and the
cellular context of the cancer itself [33–35].
In this study, we investigated whether ROR2 expression
is altered in colorectal cancers and adenomas. We also
assessed the effects of altered ROR2 expression on β-
catenin dependent Wnt signalling, proliferation, migration
and invasion properties in colorectal cancer cells.
Results
ROR2 is epigenetically silenced by promoter
hypermethylation in colorectal cancer cell lines
Quantitative reverse transcriptase polymerase chain reac-
tion (qRT-PCR) showed 23 out of 30 CRC cell lines lacked
expression of ROR2 at the mRNA level (Fig. 1a). Methyla-
tion analysis using combined bisulphite restriction analysis
(COBRA) showed 25 out of the 30 cell lines had methyla-
tion in the ROR2 promoter (Additional file 1).
Bisulphite sequencing revealed that C170 and HCT116
cell lines, which had the highest levels of ROR2 expression,
had little to no methylation across the examined promoter
molecules. SW480, SNUC2B and HCT15 cell lines which
have low levels of ROR2 expression were revealed to have
higher levels of methylation across their promoter mole-
cules. The cell lines RKO and SW620 with no detectable
levels of ROR2 expression were found to have heavy pro-
moter methylation (Fig. 1b).
Treatment of 2 methylated cell lines (SW620 and RKO)
with the DNA methyltransferase inhibitor 5-aza-2′-deoxy-
cytidine (5-aza-dC) resulted in ROR2 promoter demethyl-
ation and restoration of ROR2 expression (Fig. 1c).
Epigenetic inactivation of ROR2 is an early event in
colorectal neoplasia
To determine if ROR2 expression was also reduced in
primary tumour samples, we examined publicly available
data from The Cancer Genome Atlas (TCGA). Data
from 12 paired CRC patient samples showed that on
average, 11 of the patient primary tumours had a two-
fold decrease in ROR2 expression compared to the nor-
mal mucosa samples (P < 0.01) (Fig. 2a).
ROR2 methylation was examined in a larger cohort of
239 CRCs and 19 normal mucosa samples and significantly
greater methylation was found in the CRCs (P < 0.001)
(Fig. 2b). Examination of the RNA-Seq data within the
cohort also found significantly lower ROR2 expression (P <
0.05) in the CRCs compared to the normal (Fig. 2c). A
direct comparison of methylation and expression in the
colorectal tumour samples of the cohort revealed that
samples with high methylation (beta values > 0.25) had sig-
nificantly lower ROR2 expression (P < 0.0001) (Fig. 2e,
Additional file 2). This analysis of publicly available data re-
veals that loss of ROR2 expression is present in CRCs as well
as cell lines and that hypermethylation of the ROR2 CpG is-
land (CGI) is the cause.
To determine whether hypermethylation of the ROR2
promoter was an early or late event in colorectal neoplasia,
we compared the number of methylated samples in 88
non-invasive adenomas to 47 normal mucosa specimens.
COBRA assays revealed methylation in 80.7 % of adenomas
while only 15.5 % of the normal mucosa showed signs of
methylation (Fig. 2d). ROR2 expression and methylation
were examined in 6 adenoma samples chosen for their ab-
sence of submucosal infiltration and non-serrated histo-
logical profile (Additional file 3). qRT-PCR revealed 5 of
the 6 adenomas had reduced ROR2 expression compared
to matching normal mucosa samples. Bisulphite sequencing
showed that 4 of those adenomas were hypermethylated
across the ROR2 CGI promoter (Fig. 2f).
In vitro silencing of ROR2 in colorectal cancer increases
proliferation and migration and decreases invasion
To explore the effects of loss of ROR2 expression on Wnt
signalling, we utilised siRNA knockdown of ROR2 mRNA
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and assessed the expression of the β-catenin independent
Wnt genes JNK and NFATC1, the β-catenin dependent
genes AXIN2 and CCND1 and the epithelial-mesenchymal
transition markers VIM and CDH1. Silencing ROR2 in the
HCT116 cell line was associated with a 34 % reduction in
JNK (P < 0.01) and 29 % reduction in NFATC1 (P < 0.05)
and 31 % reduction in CCND1 (P < 0.05). ROR2 knock-
down did not result in significant changes to VIM, AXIN2
and CDH1 expression levels (Fig. 3a). To assess the effects
of ROR2 loss on cell behaviour, we next assessed prolifera-
tion, migration and invasion kinetics.
ROR2 silencing significantly increased the proliferation at
HCT116 cells (P < 0.05) (Fig. 3b). Transwell migration as-
says suggested a marginal increase in cellular migration,
though this did not reach statistical significance (P = 0.056)
(Fig. 3c). However, the ability of cells to invade through an
extracellular matrix was decreased following ROR2 silen-
cing (P < 0.01) (Fig. 3d). These data show ROR2 loss in
HCT116 cells results in changes in the expression of a spe-
cific subset of Wnt signalling genes, increases proliferation
and migration but decreases invasion.
Ectopic expression of ROR2 in RKO and SW620 cell lines
did not significantly alter cellular proliferation, migration
and invasion
ROR2 was ectopically expressed in RKO and SW620
cells using a ROR2 pFLAG plasmid (pROR2) with re-
expression of the receptor confirmed using qRT-PCR
(Fig. 4a). Following ectopic ROR2 expression in RKO
and SW620 cells, there was no significant change to
Fig. 1 ROR2 expression loss in colorectal cancer cell lines caused by promoter hypermethylation. a qRT-PCR of 30 different colorectal cancer cell
lines showing ROR2 expression normalised against 3 housekeeping genes. Insert shows the relative position of ROR2 qRT-PCR primers relative to
ROR2 gene. b Bisulphite sequencing of 7 colorectal cancer cell lines (C170, HCT116, SW480, SNUC2B, HCT15, SW620, RKO) showing increased
methylation index (MI) of ROR2 promoter correlating with decreased levels of ROR2 mRNA expression. Black squares represent methylated CpG
dinucleotides. White squares represent unmethylated CpG dinucleotides. Grey squares represent CpG dinucleotide with an inconclusive finding. Gene map
of ROR2 indicates the region of the ROR2 CpG island analysed in bisulphite sequencing. c qRT-PCR of RKO and SW620 cells after 5-aza-2-deoxycytidine
(5-aza-dC) treatment compared with control cells (n = 3). ROR2 expression was normalised against 3 housekeeping genes. Corresponding bisulphite
sequencing reveals loss of ROR2 promoter methylation and decreased methylation index (MI) resulting from 5-aza-dC treatment
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Fig. 2 ROR2 promoter hypermethylation and silencing in adenomas and patient tumour samples. a Matching normal and tumour samples from
TCGA database showing differences in ROR2 expression as assessed using Agilent microarray (n = 12) (P < 0.01). b ROR2 methylation comparison
in entire cohort of tumour and normal samples from TCGA database as assessed using Illumina Infinium (HumanMethylation450) arrays (n= 258) (P < 0.001).
Methylation values were obtained by averaging the beta values of the methylation probes that fell within the ROR2 CpG island. c Average normalised ROR2
expression in entire cohort of tumour and normal samples from TCGA database as assessed using Illumina RNA-Seq (n = 258) (P < 0.05). d Methylation
percentages in colorectal adenomas and normal samples as analysed using COBRA assays (n= 47 & n= 88 respectively). e Comparison of ROR2 expression to
methylation in colorectal tumour samples from TCGA database (n= 239) (P < 0.0001). Samples with average beta values <0.25 were categorised as low
methylation whilst samples with average beta values >0.25 were categorised as high methylation. The results shown here are based upon data generated by
the TCGA Research Network: http://cancergenome.nih.gov/. f qRT-PCR of 6 patient adenoma samples with matching normal tissue showing differences in
ROR2 expression. Expression was normalised against 3 housekeeping genes. Bisulphite sequencing revealing a corresponding change in ROR2 promoter
methylation between samples of patient adenomas and adjacent normal tissue
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Fig. 3 Increased proliferative, metastatic and invasive potential following ROR2 knockdown in HCT116 cells. a qRT-PCR of Wnt & EMT associated genes in
HCT116 cell lines after ROR2 siRNA knockdown. All expression results normalised against 3 housekeeping genes (n = 3) (P < 0.05). b CCK-8 proliferation assay
of HCT116 cells with and without ROR2 siRNA knockdown (n = 3) (P < 0.01). c Images of transwell migration assay of HCT116 cells with and without ROR2
siRNA knockdown at 10× magnification. d Average cell count comparison between HCT116 cells with and without ROR2 siRNA knockdown. Average count
taken from 4 independent image fields at 20× magnification (n = 3). e Images of transwell invasion assay of HCT116 cells with and without ROR2 siRNA
knockdown at 10× magnification. f Average cell count comparison between HCT116 cells with and without ROR2 siRNA knockdown. Average count taken
from 4 independent image fields at 20× magnification (n = 3) (P < 0.01)
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cellular proliferation (Fig. 4b). When cellular migration
was examined in RKO and SW620 cells using wound
healing assays, there was no significant change detected
between the rate of wound closure between cells with
and without ectopic ROR2 expression (Fig. 4c-f), indicat-
ing that although ROR2 knockdown may resulted in
functional changes to CRC cell lines, the same may not
be true with ectopic ROR2 expression.
Fig. 4 Functional consequences of ectopic ROR2 expression in RKO and SW620 cell lines. a ROR2 qRT-PCR of RKO and SW620 cell lines with ectopic ROR2
expression (pROR2 transfection) and control (pFLAG-CMV-4™ transfection) relative to expression in HCT116 cell lines. All expression results normalised
against 3 housekeeping genes (n = 1). b CCK-8 proliferation assay of RKO and SW620 cells with and without ectopic ROR2 expression (n = 3). c Wound
healing assay comparing percentage area of wound covered by RKO cells with and without ectopic ROR2 expression over a 4 day period (n = 1). d Images
of RKO cells in wound healing assay on day 0 and day 3 comparing cells with and without ectopic ROR2 expression. eWound healing assay comparing
percentage area of wound covered by SW620 cells with and without ectopic ROR2 expression over a 12 day period (n = 1). f Images of SW620 cells in
wound healing assay on day 0 and day 9 comparing cells with and without ectopic ROR2 expression
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Discussion
Although ROR2 is not normally expressed in mature adult
cells, evidence from prior studies indicate that it is present
in the colon epithelium as well as in parathyroid, testicular
and uterine tissue [27, 36]. Previous publications examin-
ing ROR2 in CRC found both upregulation and downregu-
lation of the receptor in CRC [27, 28]. Both publications
used qRT-PCR to document ROR2 expression in 20
matching tumour and normal samples yet report different
findings. The reasons for the conflicting results in these 2
publications remain unclear although differences in study
cohort and methodology may explain this discrepancy.
In our study, analysis using qRT-PCR found ROR2 ex-
pression loss in the majority of both CRC cell lines (n = 23)
and colorectal adenoma (n = 6) samples. In addition, ana-
lysis of 258 patient samples from the publicly available
TCGA database found a significant decrease of ROR2 ex-
pression in primary tumour samples compared to the nor-
mal mucosa, providing strong evidence that ROR2 is
downregulated in CRC.
Our study also uses COBRA and bisulphite sequencing
to show for the first time that not only is promoter hyper-
methylation present in the majority of CRC cell lines but it
is also present in early colorectal adenomas. Along with the
methylation, there was also a corresponding loss of ROR2
expression in the adenoma samples, leading us to hypothe-
sise that the observed downregulation was caused by epi-
genetic silencing through promoter hypermethylation. This
was supported by our analysis of both CRC cell lines and
primary tumours samples from the publicly available TCGA
database as well as data from the previous publication from
Lara et al. [27]. Our cell line experimentation also sup-
ported this hypothesis as ROR2 expression was restored in
RKO and SW620 cells following demethylation using the
DNA methyltransferase inhibitor 5-aza-2′deoxycytidine.
These findings of ROR2 expression loss and promoter
hypermethylation are particularly important as they have
been conducted on not only cell lines but also on clinical
samples from both adenomas and primary tumours. To-
gether, the clinical data along with the analysis and experi-
mentation of cell lines provides strong evidence that
epigenetic silencing of ROR2 through promoter hyperme-
thylation occurs early in colorectal carcinogenesis.
Although we have shown ROR2 to be epigenetically si-
lenced in the majority of CRC cases, the exact molecular
outcomes of this loss in the colon epithelium remains
unclear. Knockdown experiments confirm that ROR2 ex-
pression loss results in a subsequent decrease of the
downstream β-catenin independent Wnt genes JNK and
NFATC1. Although previous studies have shown ROR2
loss resulted in increased expression of the β-catenin
dependent Wnt target AXIN2 [23], we did not observe
this in our in vitro cell line model. Our examination of
the β-catenin dependent Wnt target AXIN2 and CCND1
not only revealed no apparent increase but CCND1 ex-
pression levels were instead found to be significantly de-
creased. A likely explanation for this difference in
findings may be the differences in the biological models
used, as the previous publication which reported in-
creased AXIN2 expression following ROR2 silencing
used in vivo mouse models incorporating the tumour
microenvironment [24]. It is possible that in our experi-
ments on an immortal cancer cell line, the cellular and
genetic context was significantly different and that the
loss of ROR2 resulted in the activation of different sig-
nalling pathways. This is supported by recent publica-
tions which show ROR2 and other Wnt associated genes
to be capable of activating both the β-catenin dependent
and β-catenin independent halves of the Wnt signalling
pathway [20, 24, 33, 34, 37]. ROR2 has been shown to
interact with different co-receptors [38, 39] and ligands
[40] as well being the target of phosphorylation by differ-
ent intracellular proteins [25, 41]. As the exact signalling
consequences of these ROR2 interactions are as yet un-
certain, it is possible that ROR2 downregulation resulted
in different signalling cascades in in vivo mice and in
immortal cancer cells.
Although there was no observed upregulation in the β-
catenin dependent Wnt target genes following ROR2
knockdown as reported in the literature [23, 24], our in
vitro assays on HCT116 cells still revealed an increase in
proliferation and migration. There was a significant in-
crease to cellular proliferation following ROR2 knockdown
while the observed increase to migration was close to sig-
nificance with a P value of only 0.056. The effect of ROR2
knockdown on cellular invasion was also investigated in
HCT116 cells, with the results revealing a decrease in
cellular invasion. These results are consistent with our
findings that ROR2 was initially lost in precancerous aden-
omas which possess no invasive properties. Analysis of
gene expression also found no changes to the key EMT-
related genes CDH1 and VIM following ROR2 knock-
down, suggesting that invasion capacity in CRC only
occurs later during disease progression. Our combined
functional analysis indicates that ROR2 downregulation
may cause increased proliferation and migration in early
non-invasive adenomas, resulting in a more metastatic
phenotype. The lack of observed increase in β-catenin
dependent Wnt target genes indicate that these changes
were not influenced by the inhibition of β-catenin
dependent Wnt signals. It is possible that ROR2 loss af-
fected both arms of the Wnt signalling pathways as had
been previously reported in breast and renal cancer,
resulting in the observed phenotypic changes [20, 33–35].
Another possibility is that the interaction between Wnt
signalling and another signalling pathway resulted in un-
expected circumstances [42–44]. It is evident that ROR2
plays a much more complex role in CRC and the Wnt
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signalling pathway than previously thought. Further inves-
tigations examining the direct interactions ROR2 has with
Wnt and EMT associated genes through techniques such
as DNA microarrays or RNA-seq would help reveal the
exact mechanism in which ROR2 affects cellular prolifera-
tion and migration in the context of CRC progression.
As we had found loss of ROR2 function to increase cel-
lular proliferation and migration, we hypothesised that re-
expression of the receptor may have the opposite effect.
However, when ROR2 was ectopically expressed in RKO
and SW620 cells, there was no significant change ob-
served in cellular proliferation and migration. This may
have been because the level of ROR2 expression generated
by plasmid transfection was significantly higher than that
of normal ROR2 expression levels. This could have ad-
versely affected Wnt signalling as certain pathways are
sensitive to the ratios of receptors and ligands [45, 46].
It is also possible that the RKO cell line was not func-
tionally affected by ectopic ROR2 expression because it
did not originate from a CRC caused by aberrant Wnt sig-
nalling. Although ~94 % of CRC cases possess a mutation
in a Wnt pathway gene with APC being the gene most
predominantly mutated [6], not all CRC cases arise from a
dysfunctional Wnt signalling pathway. A significant pro-
portion of CRC cases result from other causes such as
mutations and methylation in mismatch repair (MMR)
genes [47, 48]. RKO cells do not have a mutant APC gene
but they do have methylated MMR genes as well as pos-
sessing the CpG island methylator phenotype [49]. This
suggests that RKO cells originally became carcinogenic
through methylation and loss of function in MMR genes
rather than through aberrant Wnt signalling.
In SW620 cells, the absence of any change in prolifera-
tion and migration following ectopic ROR2 expression
may have been because the cell line originated from a
secondary tumour site. SW620 and SW480 cells origi-
nated from the same patient with SW620 cells obtained
from a lymph node metastasis while SW480 were from
the primary tumour [50]. Having already metastasised to
a secondary site, SW620 cells would possess a markedly
different genetic composition than that of a primary
tumour and may be resistant to any functional effects
resulting from restoration of expression in an early gene
target such as ROR2.
This is a potential issue for all cell line models as they
are cancer cells that are different to the colorectal aden-
omas in which we believe ROR2 methylation and expres-
sion loss first occurs. To truly determine if early ROR2
loss is involved in CRC progression in adenomas, a bio-
logical model which more closely resembles colorectal ad-
enomas would be needed. Future research could possibly
investigate functional effects of ROR2 loss in colorectal
adenomas grown in in vitro organoids [51]. Another pos-
sibility would be to use an inducible mouse knockout
model that targeted ROR2 in the colon. Using a mouse
strain that had a high prevalence for adenomas such as
the APC heterozygous 57BL/6 J-ApcMin/J mouse line,
would allow for the determination of whether or not early
ROR2 loss potentiates adenoma growth and development.
Conclusion
Our study has found that ROR2 promoter hypermethyla-
tion and subsequent expression loss is an early event in
CRC progression that first occurs in non-invasive aden-
omas. ROR2 expression was found to be downregulated in
the majority of CRC cases, with subsequent in vitro ex-
perimentation indicating that the silencing of the receptor
may facilitate increased cellular proliferation and migra-
tion. Although it was hypothesised that hyperactivation of
the β-catenin dependent Wnt signals was the cause, de-
creases in both β-catenin dependent and independent
genes following ROR2 knockdown suggested that the ef-
fects of ROR2 modulation are context dependent and that
the observed effects on proliferation and migration may
be influence by interactions with pathways other than β-
catenin dependent Wnt [35, 43, 52, 53]. Future research
investigating the interaction of ROR2 with various Wnt
and EMT associated proteins would help elucidate the
exact mechanism in which ROR2 affects cellular prolifera-
tion and migration. Examination of ROR2 loss in a more
adenoma like biological model instead of in cancer cell
lines would also aide in determining if the silencing of the
receptor promoted CRC progression.
Methods
Cell lines
All colorectal cancer cells were obtained from ATCC
(American Type Culture Collection, Manassas, VA,
USA). HCT116 cells were cultured in McCoy’s media
(Life Technologies, Rockville, MD) supplemented with
10 % foetal bovine serum, 1× glutamine (200 mM) and
penicillin/streptomycin (10 units/ml). RKO cells were
cultured in RPMI media (Life Technologies, Rockville,
MD) supplemented with 10 % foetal bovine serum, 1×
glutamine (200 mM) and penicillin/streptomycin (10
units/ml). SW620 cells were cultured in DMEM (Life
Technologies, Rockville, MD) supplemented with 10 %
foetal bovine serum, 1× glutamine (200 mM) and peni-
cillin/streptomycin (10 units/ml). Cells were grown in
incubators with humidified atmosphere of 5 % CO2 at
37 °C. Cells were tested on a monthly basis to ensure
there was no mycoplasma contamination.
ROR2 pFLAG plasmid construction
A ROR2 pFLAG plasmid (pROR2) was constructed by iso-
lating the ROR2 cDNA transcript from the Addgene ROR2
plasmid using Primer 1 (CTGATATCGATGGCCCGGG
GCTCGGCGCTCCCGC) and Primer 2 (TCCTCTAGAT
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CAAGCTTCCAG CTGGACTTGG). The resulting PCR
fragment then underwent restriction enzyme digestion with
both EcoRV and XbaI. The DNA was then subcloned into
the pFLAG-CMV™-4 plasmid containing an N-terminal
epitope tag following a similar restriction enzyme digest.
ROR2 siRNA Knockdown
Cells were seeded at 1 × 106 cells into 60 mm plates
(Nunc™, Thermo Fisher Scientific, Rockford, IL USA)
and allowed to adhere over a 6 h period. Cells were then
serum starved for 18 h before being transfected with ei-
ther 60 pmoles of ROR2 siRNA or scrambled control
siRNA (Life Technologies, Rockville, MD). siRNA were
premixed in 250 μl of serum free McCoy’s media (Life
Technologies, Rockville, MD). siRNA mixture was then
combined with 6 μl of Lipofectamine® 2000 (Life Tech-
nologies, Rockville, MD) premixed in 250 μl of serum
free McCoy’s media before addition to cells. After trans-
fection, cells were incubated at 5 % CO2 at 37 °C before
being used in subsequent experimentation.
Ectopic ROR2 expression
Cells were seeded at 1 × 106 cells into 60 mm plates
(Nunc™, Thermo Fisher Scientific, Rockford, IL USA)
and allowed to adhere over a 6 h period. Cells were then
serum starved for 18 h before being transfected with ei-
ther 1.4 μg of empty pFLAG-CMV™-4 plasmid or 1.4 g
of pmoles of ROR2 pFLAG plasmid. Plasmid solutions
were premixed in 250 μl of serum free RPMI media (Life
Technologies, Rockville, MD) for RKO cells and DMEM
(Life Technologies, Rockville, MD) for SW620 cells. The
plasmid solutions were then combined with 6 μl of Lipo-
fectamine® 2000 (Life Technologies, Rockville, MD) pre-
mixed in 250 μl of the appropriate serum free media
before addition to cells. After transfection, cells were in-
cubated at 5 % CO2 at 37 °C before being used in subse-
quent experimentation.
Quantitative real time PCR
Cell samples underwent cell lysis using 2-mercaptoethanol
and RNA extraction was carried out using the RNeasy Ex-
traction Kit (Qiagen 74106). 1 μg of RNA was quantified
and treated with RNase-free DNase (Life Technologies
18068–015). The DNase treated RNA was used for cDNA
synthesis using Quantitect cDNA synthesis kit (Qiagen
205313) with appropriate negative controls. The primer se-
quence used for ROR2 qRT-PCR was designed to amplify a
region which included all known transcript variants of
ROR2 (Forward 5′-GTCCAACGCACAGCCCAAATC-3′
& Reverse 5′-CCGGTTGCCAATGAAGCGTG-3′). qRT-
PCR was performed using SYBR® Mastermix Reagent
(Qiagen 204056) and the M× 5000p Thermal Cycler. Each
sample was run in triplicate and the experiment was run
for 40 cycles. ROR2 results and those of Wnt & EMT
related genes (AXIN2, CCND1, JNK, NFATC1, CDH1,
VIM) were normalised against 3 house-keeping genes
(SDHA, RPL13A, HSP90AB1). Primer sequences for add-
itional genes can be found in Additional file 4. ROR2
knockdown qRT-PCR experiments were repeated in tripli-
cate and statistical significance was evaluated using un-
paired t-test.
Combined bisulphite restriction analysis (COBRA) Assay
DNA was extracted from samples before undergoing
bisulphite treatment using Ez DNA Methylation™ – Gold
Kit (Zymo Research, Australia). The ROR2 promoter re-
gion was amplified using ROR2 COBRA semi-nested
primers which covered a 436 bp region of the 1958 bp
ROR2 CpG island where MBD-Seq data indicated the
greatest level of coverage. (Forward 5′-GGGTTAYGTT-
TATTTTAGGATTTTGTTAGGT-3′ & Forward nested
5′-GTYGTGTGTTTTTGAAGGAGGAAGATT-3′ & Re-
verse 5′-CTCTCAATATCCCRAACTTCAAATAAAATC-
TAA-3′). The PCR product was digested with TaqI
restriction enzyme (Fermentas) before undergoing gel
electrophoresis in a 1.5 % agarose gel. Resulting bands
were visualised under UV light.
Bisulphite sequencing
DNA was extracted from samples before undergoing
bisulphite treatment using Ez DNA Methylation™ – Gold
Kit (Zymo Research, Australia). ROR2 COBRA semi-
nested primers were used to amplify the ROR2 CpG is-
land region. The resulting PCR product was then ligated
into pCR™2.1-TOPO® plasmid (Life Technologies, Rock-
ville, MD) before being transformed into chemically
competent DH5α™ E. coli bacteria. The bacteria were
utilised to clone the PCR product before being plated
onto LB agar plates for blue white selection. Bacteria
which contained pCR™2.1-TOPO® plasmid with ROR2
PCR inserts were sequenced using BigDye® (Life Tech-
nologies, Rockville, MD) with ROR2 Reverse and Forward
nested primers before undergoing Sanger sequencing
(Ramaciotti Centre, UNSW Australia).
5-aza-2-deoxycytidine treatment
Cells were seeded at 1 × 106 cells into 60 mm plates
(Nunc™, Thermo Fisher Scientific, Rockford, IL USA)
and allowed to adhere over a 24 h period. Cells were
subsequently treated to 2.5 μM concentrations of 5-aza-
2-deoxycytidine (Sigma A3656). Treatment was repeated
every 24 h over a 72 h period. Control cells were treated
with the vehicle control of acetic acid instead of 5-aza-2-
deoxycytidine.
Data analysis of TCGA cohort
Normalised ROR2 expression and methylation data of
tumour and matched normal tissue were obtained from
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The Cancer Genome Atlas (http://cancergenome.nih.gov/)
and analysed by Agilent microarrays and Illumina HiSeq
2000 RNA Sequencing. Methylation values were analysed
using Illumina Infinium (HumanMethylation450) arrays
and the beta-value average was obtained from methylation
probes that fell within the 1958 bp ROR2 CpG island. Stat-
istical significance of matched patient tumour and normal
samples were carried out using paired t-test. Statistical sig-
nificance of expression and methylation comparison of the
entire cohort was evaluated using unpaired t-test. Statistical
significance of expression in low and high methylation sam-
ples was evaluated using unpaired t-test. The results shown
in these analyses are in whole or part based upon data gen-
erated by the TCGA Research Network; http://cancergen-
ome.nih.gov/.
Patient samples
Forty-seven normal and 88 adenoma samples were col-
lected from patients at Westmead Hospital using endo-
scopic mucosal resection (Ethics committee approval
number 2008/6/4.6 and 11194, Sydney West Area
Health Service Human Research and Ethics Committee)
[54]. A further six fresh colorectal adenomas and paired
adjacent normal mucosa samples were taken from surgi-
cal resection specimens from 3 males and 3 females at
St Vincent’s Hospital, Sydney (Ethics committee ap-
proval number H00/022 and 00113) [55]. Informed con-
sent was obtained from all patients participating in the
study. The adenomas obtained showed no evidence of
invasive malignancy (Additional file 3).
Proliferation assay
Twenty four h after ROR2 siRNA transfection, ROR2
knockdown and control HCT116 cells were lifted using
1× 0.5 % Trypsin EDTA and seeded into a clear 96-well
well plate (Nunc™, Thermo Fisher Scientific, Rockford,
IL USA) at 1 × 104 cells/well. Cells were allowed to ad-
here for 2 h before 3 wells of ROR2 knockdown cells
and 3 wells of control cells were treated with 10 μl of
CCK-8 reagent (Dojindo Molecular Technologies, Inc.
Rockville, MD) before the plate was wrapped in foil.
10 μl of CCK-8 reagent was also added to 3 media only
wells to act as control blank readings. 2 h after addition
of CCK-8 reagent, the treated wells were read on Spec-
tramax 190 plate reader at 450 nm absorbance using the
media only wells as blank readings. CCK-8 reagent was
applied to additional triplicate wells at 24 & 48 h after
the initial seeding and their 450 nm absorbance was read
to determine changes in cellular proliferation. All subse-
quent readings for each siRNA treatment was normal-
ised against the initial reading 2 h after seeding. The
experiment was repeated in triplicate and statistical sig-
nificance was evaluated using 2 way ANOVA.
Migration assay
Seven hundred μl of media supplemented with 20 %
foetal bovine serum was added to the lower chamber of
transwell migration plates while 200 μl of media supple-
mented with 1 % foetal bovine serum was added to the
insert (Corning Incorporated – Life Sciences, One Bec-
ton Circle Durham, NC 27712 USA). 24 h after ROR2
siRNA transfection, knockdown and control HCT116
cells were lifted using 1× 0.5 % Trypsin EDTA and re-
suspended in 1 % FBS media to a concentration of 7 ×
105 cells/ml. 100 μl of cell solution was added to the in-
serts. The plates were incubated for 48 h at 37 °C before
the inserts were removed and washed twice in PBS.
Cells were then fixed with 100 % methanol for 20 min
before again being washed twice in PBS. Inserts were
then stained with 1 % crystal violet for 30 min before
being washed twice in PBS. Non-migrated cells on the
upper surface of inserts were removed using cotton
swabs. The transwell membrane was then excised and
mounted onto a glass slide with mounting medium
(Dako CS70330-2). 4 independent field counts at 20×
magnification using ImageQuant TL Software were used
to assess cell numbers. The experiment was repeated in
triplicate and statistical analysis was evaluated using un-
paired t-test.
Invasion assay
Transwell invasion plates with pre-coated matrigel
were first rehydrated using warm serum free media for
2 h at 37 °C. Media was then removed and 750 μl of
media supplemented with 20 % foetal bovine serum
was added to the lower chamber while 100 μl of serum
free media was added to the insert (Corning Incorpo-
rated–Life Sciences, One Becton Circle Durham, NC
27712 USA). 24 h after ROR2 siRNA transfection,
knockdown and control HCT116 cells were lifted using
1× 0.5 % Trypsin EDTA and resuspended in 1 % FBS
media to a concentration of 7 × 105 cells/ml. 200 μl of
cell solution was added to the inserts. The plates were
incubated for 48 h at 37 °C before the inserts were re-
moved and washed twice in PBS. Cells were then fixed
with 100 % methanol for 20 min before again being
washed twice in PBS. Inserts were then stained with
1 % crystal violet for 30 min before being washed twice
in PBS. Non-migrated cells on the upper surface of in-
serts were removed using cotton swabs. The transwell
membrane was then excised and mounted onto a glass
slide with mounting medium (Dako CS70330-2). 4 in-
dependent field counts at 20× magnification using
ImageQuant TL Software were used to assess cell
numbers. The experiment was repeated in triplicate
and statistical analysis was evaluated using unpaired t-
test.
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Additional files
Additional file 1: COBRA of CRC cell lines showing methylation in majority
of samples. COBRA assays on 31 colorectal cancer cell lines reveals that 26 of
the cell lines possessed some level of ROR2 methylation. (EPS 3931 kb)
Additional file 2: ROR2 methylation and expression correlation. Analysis
of correlation between ROR2 methylation and expression in 239 primary
tumour samples from TCGA dataset. (EPS 568 kb)
Additional file 3: Table of qRT-PCR Primer Sequences. Histopathological
information on adenoma samples and matching normal mucosa. Age ranges
of patients 57–79. Samples listed in order from top to bottom in Fig 2F.
(TXT 552 bytes)
Additional file 4: Table of qRT-PCR Primer Sequences. List of qRT-PCR
primer sequences used in experimentation. (TXT 726 bytes)
Abbreviations
5-aza-dC, 5-aza-2′-deoxycytidine; ATCC, American Type Culture Collection; CGI,
CpG island; COBRA, combined bisulphite restriction analysis; CRC, colorectal
Cancer; MI, methylation index; MMR genes, Mismatch repair genes; PCP, planar
cell polarity; qRT-PCR, quantitative reverse transcriptase polymerase chain
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